본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

인슐린양 성장 인자 결합 단백-3 유전자 -202 좌위의 다형성에 따른 비소세포폐암의 위험도
Promoter -202 A/C Polymorphism of Insulin-like Growth Factor Binding Protein-3 Gene and Non-small Cell Lung Cancer Risk

문진욱    (연세대학교 의과대학 내과학교실   ); 장윤수    (연세대학교 의과대학 내과학교실   ); 한창훈    (연세대학교 의과대학 내과학교실   ); 강신명    (연세대학교 의과대학 내과학교실   ); 박무석    (연세대학교 의과대학 내과학교실   ); 변민광    (연세대학교 의과대학 내과학교실   ); 정우영    (연세대학교 의과대학 내과학교실   ); 박재준    (연세대학교 의과대학 내과학교실   ); 유경남    (연세대학교 의과대학 BK21 의과학 사업단   ); 신주혜    (연세대학교 의과대학 암전이 연구센터   ); 김영삼    (연세대학교 의과대학 내과학교실   ); 장준    (연세대학교 의과대학 내과학교실   ); 김성규    (연세대학교 의과대학 내과학교실   ); 김희정    (연세대학교 의과대학 병리학교실   ); 김세규    (연세대학교 의과대학 내과학교실  );
  • 초록

    인슐린양 성장 인자 결합 단백-3(Insulin-like growth factor (IGF) binding protein-3 (IGFBP-3))는 혈액 내에서 IGF와 결합하여 복합체 혹은 저장소로 작용함으로써, IGF가 수용체에 결합하는 것을 방해하여 IGF의 항세포사멸(antiapoptosis) 및 세포분열 촉진의 기능을 억제한다. 하지만, 특정 상황에서는 도리어 IGFBP-3가 IGF의 파괴를 억제하여 IGF에 의한 암세포의 분화 및 성장을 촉진할 수도 있다는 것이 알려져 있다. 대부분의 환자에서 혈액내 IGFBP-3 수치는 IGFBP-3 유전자의 -202 좌위(locus)의 다형성(polymorphism)에 의해 크게 영향을 받는다. 따라서, 저자 등은 제한 효소(restriction enzyme)를 이용하여 비소세포폐암 환자의 IGFBP-3 유전자 -202 좌위의 다형성을 분석함으로써, 이 좌위의 다형성이 비소세포폐암의 위험도와 연관되어 있는지 조사하였다. 본 연구는 104명의 비소세포폐암 환자군과, 연령, 성별, 흡연력이 비슷한 104명의 대조군을 비교 분석하였다. 대조군에서 -202 좌위 유전자 다형성의 빈도는 AA형 48명 (46.2%), AC형 45명 (43.3%), CC형 11명 (10.5%)이었고, 비소세포폐암 환자군에서 -202 좌위 유전자 다형성의 빈도는 AA형 67명(64.4%), AC형 35명 (33.7%), CC형 2명 (1.9%)이었다. -202 좌위의 유전자 다형성에 있어서 대조군과 비소세포폐암 환자군 사이에 유의한 빈도 차이가 있었으며 (p


    Background : IGFBP-3 inhibits the mitogenic and anti-apoptotic activity of IGF by blocking the binding of IGF to its receptor. However, under certain circumstances, IGFBP-3 can enhance the activity of IGF by protecting IGF from its degradation. More than half of the interindividual variations in IGFBP-3 levels are known to be genetically determined by the polymorphism at -202 locus of IGFBP-3 gene. Method : We attempted to ascertain whether A-202C polymorphic variation of IGFBP-3 gene constitutes a risk factor for non-small cell lung cancer (NSCLC), using PCR-restriction fragment length polymorphism (RFLP). Our study included 104 NSCLC patients and 104 age-, gender-, and smoking status-matched control subjects. Result : In the 104 NSCLC subjects, the genotypic frequencies at the -202 site were as follows: AA = 67 (64.4%), AC = 35 (33.7%), and CC = 2 (1.9%). We did detect significant differences in the genotypic distribution between the NSCLC and the control subjects (p AC>CC). Using CC genotype as a reference, the odds ratio (OR) for the subjects with AC genotype was 2.60 (95% CI: 0.89 - 8.60), and the OR associated with AA genotype was 5.89 (95% CI: 1.92 - 21.16). Conclusion : These results indicate that the dysregulation of IGF axis should now be considered as another important risk factor for NSCLC, and a potential target for novel antineoplastic therapies and/or preventative strategies in high-risk groups.


  • 주제어

    Insulin-like growth factor (IGF) .   Insulin-like growth factor binding protein-3 (IGFBP-3) .   Non-small cell lung cancer (NSCLC) .   Promoter -202 A/C polymorphism .   Restriction fragment length polymorphism (RFLP).  

  • 참고문헌 (38)

    1. Adamo ML, Shao ZM, Lanau F, Chen JC, Clemmons DR, Roberts CT Jr, et al. Insulin-like growth factor-I (IGF-I) and retinoic acid modulation of IGF-binding proteins (IGFBPs): IGFBP-2, -3, and -4 gene expression and protein secretion in a breast cancer cell line. Endocrinology 1992;131:1858-66 
    2. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995;377:646-9 
    3. Huynh H, PollakM, Zhang JC. Regulation of insulinlike growth factor (IGF) II and IGF binding protein-3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite $1.25(OH)_2D3$ and its analog EB1089. Int J Oncol 1998;13:137-43 
    4. Conover CA, de Leon DD. Acid-activated insulin-like growth factor-binding protein-3 proteolysis in normal and transformed cells: role of cathepsin D. J Biol Chem 1994;269:7076-80 
    5. Harrela M, Koistinen H, Kaprio J, Lehtovirta M, Tuomilehto J, Eriksson J, et al. Genetic and envir- onmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest 1996;98:2612-5 
    6. Schernhammer ES, Hankinson SE, Hunter DJ, Blouin MJ, Pollak MN. Polymorphic variation at the -202 locus in IGFBP3: influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk. Int J Cancer 2003;107:60-4 
    7. Fletcher O, Gibson L, Johnson N, Altmann DR, Holly JM, Ashworth A, et al. Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 2005;14:2-19 
    8. de Mellow JS, Baxter RC. Growth hormone-dependent insulin-like growth factor (IGF) binding protein both inhibits and potentiates IGF-I-stimulated DNA synthesis in human skin fibroblasts. Biochem Biophys Res Commun 1988;156:199-204 
    9. Lee WL, Chen JW, Ting CT, Lin SJ, Wang PH. Changes of the insulin-like growth factor I system during acute myocardial infarction: implications on left ventricular remodeling. J Clin Endocrinol Metab 1999;84:1575?81 
    10. Spagnoli A, Chiarelli F, Vorwerk P, Boscherini B, Rosenfeld RG. Evaluation of the components of insulin-like growth factor (IGF)-IGF binding protein (IGFBP) system in adolescents with type 1 diabetes and persistent microalbuminuria: relationship with increased urinary excretion of IGFBP-3 18kD N-terminal fragment. Clin Endocrinol 1999;51:587-96 
    11. Shinada M, Akdeniz A, Panagiotopoulos S, Jerums G, Bach LA. Proteolysis of insulin-like growth factor-binding protein-3 is increased in urine from patients with diabetic nephropathy. J Clin Endocrinol Metab 2000;85:1163-9 
    12. Nickerson T, Pollak M. Bicalutamide (Casodex)-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins. Urology 1999;54:1120-5 
    13. Rozen F, Zhang J, Pollak M. Antiproliferative action of tumor necrosis factor-alpha on MCF-7 breast cancer cells is associated with increased insulin-like growth factor binding protein-3 accumulation. Int J Oncol 1998;13:865-9 
    14. Watanabe T, Itokawa M, Nakagawa Y, Iguchi T, Katagiri T. Increased levels of insulin-like growth factor binding protein-3 in hypertensive patients with carotid atherosclerosis. Am J Hypertens 2003;16:754-60 
    15. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34 
    16. Huynh H, Nickerson T, PollakM, Yang X. Regulation of insulin-like growth factor I receptor expression by the pure antiestrogen ICI 182780. Clin Cancer Res 1996;2:2037-42 
    17. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6 
    18. Gucev ZS, Oh Y, Kelley KM, Rosenfeld RG. Insulinlike growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells. Cancer Res 1996;56:1545-50 
    19. Pratt SE, Pollak MN. Insulin-like growth factor binding protein 3 (IGF-BP3) inhibits estrogen-stimulated breast cancer cell proliferation. Biochem Biophys Res Commun 1994;198:292-7 
    20. Wang L, Habuchi T, Tsuchiya N, Mitsumori K, Ohyama C, Sato K, et al. Insulin-like growth factor-binding protein-3 gene -202 A/C polymorphism is correlated with advanced disease status in prostate cancer. Cancer Res 2003;63:4407-11 
    21. Brosius FC 3rd. Trophic factors and cytokines in early diabetic glomerulopathy. Exp Diabesity Res 2003;4:225-33 
    22. Parrizas M, LeRoith D. Insulin-like growth factor-1 inhibition of apoptosis is associated with increased expression of the bcl-xL gene product. Endocrinology 1997;138:1355-8 
    23. Walker GE, Wilson EM, Powell D, Oh Y. Butyrate, a histone deacetylase inhibitor, activates the human IGF binding protein-3 promoter in breast cancer cells: molecular mechanism involves an Sp1/Sp3 multiprotein complex. Endocrinology 2001;142:3817-27 
    24. Oh Y, Muller HL, Ng L, Rosenfeld RG. Transforming growth factor-beta-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J Biol Chem 1995;270:13589-92 
    25. Dunn SE, Hardman RA, Kari FW, Barrett JC. Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL 100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res 1997;57:2687-93 
    26. Prager D, Li HL, Asa S, Melmed S. Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. Proc Natl Acad Sci U S A 1994;91:2181-5 
    27. Chang YS, Wang L, Liu D, Mao L, Hong WK, Khuri FR, et al. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res 2002;8:3669-75 
    28. Kao PC, Matheny AP Jr, Lang CA. Insulin-like growth factor-I comparisons in healthy twin children. J Clin Endocrinol Metab 1994;78:310-2 
    29. Deal C, Ma J, Wilkin F, Paquette J, Rozen F, Ge B, et al. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 2001;86:1274-80 
    30. Ren Z, Cai Q, Shu XO, Cai H, Li C, Yu H, et al. Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women. Cancer Epidemiol Biomarkers Prev 2004;13:1290-5 
    31. Werner H, Karnieli E, Rauscher FJ, LeRoith D. Wildtype and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci U S A 1996;93:8318-23 
    32. Cohen P, Graves HC, Peehl DM, Kamarei M, Guidice LC, Rosenfeld RG. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992;75:1046-53 
    33. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, et al. Prospetive study of colorectal cancer risk in men and plasma levels of insulin-like growth factor(IGF)-1 and IGF-binding protein-3. J Natl Cancer Inst 1999;91:620-5 
    34. Stewart CE, Rotwein P. Growth, differentiation, and survival: multiple physiological functions for insulinlike growth factors. Physiol Rev 1996;76:1005-26 
    35. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-6 
    36. Chen JC, Shao ZM, Sheikh MS, Hussain A, LeRoith D, Roberts CT Jr, et al. Insulin-like growth factorbinding protein enhancement of insulin-like growth factor-I (IGF-I)-mediated DNA synthesis and IGF-I binding in a human breast carcinoma cell line. J Cell Physiol 1994;158:69-78 
    37. Macauly VM. Insulin-like growth factors and cancer. Br J Cancer 1992;65:311-20 
    38. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 1999;91:151-6 

 저자의 다른 논문

  • 문진욱 (31)

    1. 2003 "Detection of Lymphomatous Marrow Infiltration using F-18 FDG PET at Initial Staging and after chemotherapy" 大韓核醫學會誌 = Korean journal of nuclear medicine 37 (3): 171~177    
    2. 2003 "기관지내 호지킨씨 림프종 1예" 결핵 및 호흡기 질환 = Tuberculosis and respiratory diseases 54 (6): 640~644    
    3. 2003 "폐암의 골전이에서 $^{99m}Tc$ MDP 골주사와 전신 $^{18}FDG$ PET의 비교" 결핵 및 호흡기 질환 = Tuberculosis and respiratory diseases 55 (3): 280~286    
    4. 2003 "Bleomycin 투여 후 발생한 폐쇄세기관지기질화폐렴" 결핵 및 호흡기 질환 = Tuberculosis and respiratory diseases 55 (3): 311~316    
    5. 2003 "성인에서 발생한 중배엽성 신종의 폐전이 1예" 결핵 및 호흡기 질환 = Tuberculosis and respiratory diseases 55 (4): 402~407    
    6. 2004 "원발성 종격동 종양 및 낭종의 진단과 치료 -단일 대학병원에서의 42년 보고-" 결핵 및 호흡기 질환 = Tuberculosis and respiratory diseases 56 (1): 29~39    
    7. 2004 "폐동맥고혈압 진단에 있어 N-terminal Pro-brain Natriuretic Peptide 측정의 유용성" 결핵 및 호흡기 질환 = Tuberculosis and respiratory diseases 56 (1): 67~76    
    8. 2004 "대량객혈로 내원한 대동맥기관지루 1예" 결핵 및 호흡기 질환 = Tuberculosis and respiratory diseases 56 (4): 405~410    
    9. 2004 "악성 흉막액에서 CEA와 CYFRA 21-1의 진단적 유용성" Tuberculosis and respiratory diseases : TRD = 결핵 및 호흡기 질환 57 (1): 32~36    
    10. 2004 "골수이식 후 만성 이식편대숙주질환으로 발생한 폐쇄성 세기관지염에 의한 이차성 재발성 기흉 1례" Tuberculosis and respiratory diseases : TRD = 결핵 및 호흡기 질환 57 (2): 183~187    
  • 장윤수 (45)

  • 한창훈 (25)

  • 강신명 (24)

  • 박무석 (109)

  • 변민광 (49)

  • 정우영 (29)

  • 박재준 (1)

  • 유경남 (1)

  • 신주혜 (5)

  • 김영삼 (130)

  • 장준 (165)

  • 김성규 (163)

  • 김희정 (1)

  • 김세규 (165)

 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

무료다운로드
  • NDSL :
  • 대한결핵 및 호흡기학회 : 저널
유료다운로드

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기